Jazz Pharmaceuticals (JAZZ) reported fourth quarter adjusted net income of $1.17 per share after the close Monday, compared to $0.63 per share in the previous year. The consensus estimate was for EPS of $1.09. The stock is now up 0.97 on 20K shares.
Jazz Pharmaceuticals traded in a range throughout Monday's session and closed down by 0.26 at $50.55. The stock pulled back from the upper end of over a month and a half long range, at the highs of the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.